Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome

References

• Wolf WM, Wattick RA, Kinkade ON, et al. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018;15(11):2589.
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Ehrmann DA Clinical manifestations of polycystic ovary syndrome in adults. In: UpToDate; Post TW (Ed); UpToDate; Waltham; MA ( Accessed on 2021 Mar 24).
   Google Scholar
• Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. Am Fam Physician. 2016;94(2):106–113.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.
   Web of Science ®Google Scholar
• Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2020;105(9). https://doi.org/10.1210/clinem/dgaa426.
   Google Scholar
• Barbieri RL, Ehrmann DA Treatment of polycystic ovary syndrome in adults. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA ( Accessed on 2021 Mar 24).
   Google Scholar
• del Olmo-Garcia MI, Merino-Torres JF. GLP-1receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:2018.
   Web of Science ®Google Scholar
• Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181–187.
   PubMed Web of Science ®Google Scholar
• Lee J, Hong SW, Rhee EJ, et al. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes and Metabolism Journal. 2012;36(4):262.
   Google Scholar
• Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Vol. 11. The review of diabetic studies : RDS; Germany. 2014.
   Google Scholar
• Traub ML. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World J Diabetes. 2011;2(3):3.
   Google Scholar
• Oliver-Williams C, Vassard D, Pinborg A, et al. Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study. Eur J Prev Cardiol. 2020. https://doi.org/10.1177/2047487320939674
   Web of Science ®Google Scholar
• Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2021. https://doi.org/10.1111/cen.14421
   Google Scholar
• Paschou SA, Polyzos SA, Anagnostis P, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Vol. 67, Endocrine. 2020.
   Google Scholar
• Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, et al. Are women with polycystic ovarian syndrome at a high risk of nonalcoholic fatty liver disease; A meta-analysis. Vol. 14. Hepatitis Monthly; Iran. 2014.
   Google Scholar
• Zheng S, Liu E, Zhang Y, et al. Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment. Endocr J. 2019;66(6):555–562.
   Web of Science ®Google Scholar
• Zheng S, Zhang Y, Long T, et al. Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women. Obes Med. 2017;7(7):15–20.
   Google Scholar
• Jensterle M, Kravos NA, Goričar K, et al. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017;17(1).
   PubMed Web of Science ®Google Scholar
• Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. In Expert Review of Clinical Pharmacology. England. 2017 Apr;10(4):401-408.
   Google Scholar
• Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670–2678.
   PubMed Web of Science ®Google Scholar
• Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne). 2014 AUG;5:5.
   PubMed Web of Science ®Google Scholar
• Kahal H, Aburima A, Ungvari T, et al. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord. 2015;15(1). https://doi.org/10.1186/s12902-015-0005-6.
   Google Scholar
• Jensterle M, Salamun V, Kocjan T, et al. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015;8(1):1.
   PubMed Web of Science ®Google Scholar
• Jensterle Sever M, Kocjan T, Pfeifer M, et al. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):3.
   Web of Science ®Google Scholar
• Jensterle M, Kravos NA, Pfeifer M, et al. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. In Hormones. Athens, Greece. 2015;14(1):81-90. DOI: https://doi.org/10.1007/BF03401383.
   Google Scholar
• Šalamon V, Jensterle M, Janež A, et al. Short term intervention with liraglutide and metformin increased fertility potential in a subset of obese PCOS proceeding IVF. Endocr Abstr [Internet]. 2017 May 3; [cited 2021 Mar 24]. Available from: http://www.endocrine-abstracts.org/ea/0049/ea0049ep1105.htm
   Google Scholar
• Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study. Exp Ther Med. 2016;11(4):4.
   Web of Science ®Google Scholar
• Salamun V, Jensterle M, Janez A, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1.
   PubMed Web of Science ®Google Scholar
• Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):1.
   PubMed Web of Science ®Google Scholar
• Jensterle M, Kocjan T, Kravos NA, et al. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. 2015;40(3):3.
   Web of Science ®Google Scholar
• Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reproductive BioMedicine Online; United Kingdom. 2019.
   Google Scholar
• Lyu X, Lyu T, Wang X, et al. The antiobesity effect of GLP-1 receptor agonists alone or in combination with metformin in overweight/obese women with polycystic ovary syndrome: a systematic review and meta-analysis. pintaudi B, editor. Int J Endocrinol [Internet]. Feb 13 2021;1–11. Available from. ;. https://www.hindawi.com/journals/ije/2021/6616693/
   Google Scholar
• Dawson AJ, Sathyapalan T, Vince R, et al. The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2019;10: https://doi.org/10.3389/fendo.2019.00189.
   Google Scholar
• Kahal H, Kilpatrick E, Rigby A, et al. The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls. Gynecol Endocrinol. 2019;35(2):2.
   Web of Science ®Google Scholar
• Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous gastrostomy device for the treatment of class II and Class III Obesity: results of a Randomized Controlled Trial. Am J Gastroenterol. 2017;112(3):447–457.
   Web of Science ®Google Scholar
• Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–880.
   PubMed Web of Science ®Google Scholar
• Clifton PM, Keogh JB. Effects of Different Weight Loss Approaches on CVD Risk. Curr Atheroscler Rep [Internet]. 2018 Jun 25;20(6):27. Available from: http://link.springer.com/10.1007/s11883-018-0728-8
   PubMed Web of Science ®Google Scholar
• Nylander M, Frøssing S, Kistorp C, et al. Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocr Connect. 2017;6(2):2.
   Web of Science ®Google Scholar
• Li R, Zheng S, Mai T, et al. 1341-P: comparison of the Effects of Metformin and Exenatide on Pregnancy Rate and Outcomes in Overweight or Obese PCOS Women. Diabetes [Internet]. 2020 Jun 9;69(Supplement 1): 1341.
   PubMed Web of Science ®Google Scholar
• Janez A, Jensterle M. GLP-1 Receptor Agonist Liraglutide Increased IVF Pregnancy Rates in Obese Women with PCOS and Previous Poor Response to First-Line Reproductive Treatments. Diabetes [Internet]. 2018 May;67(Supplement 1): P.1465.
   Web of Science ®Google Scholar
• Tao T, Zhang Y, Zhu Y-C, et al. Exenatide, Metformin, or Both for Prediabetes in PCOS: a Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1420-e1432.
   Web of Science ®Google Scholar
• Classification and diagnosis of diabetes: standards of Medical Care in Diabetes-2020. American Diabetes Association. Diabetes Care. 2020 Jan; 43(Supplement 1):S14-S31. https://doi.org/10.2337/dc20-S002
   Google Scholar
• Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 87(6): 767–774. 2017. .
   Web of Science ®Google Scholar
• Frøssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2018;20(1):1.
   Web of Science ®Google Scholar
• Tang L, Yuan L, Yang G, et al. Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients. Clin Endocrinol (Oxf). 2019;91(4):4.
   Web of Science ®Google Scholar
• Frøssing S, Nylander M, Kistorp C, et al. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocr Connect. 2018;7(1):1.
   PubMed Web of Science ®Google Scholar
• Yang M, Liu R, Li S, et al. Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: ross-sectional and interventional studies in normal subjects, insulinresistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care. 2013;36(5):5. .
   Google Scholar
• Lai Y, Chen J, Li L, et al. Circulating Zinc-α2-glycoprotein levels and insulin resistance in polycystic ovary syndrome. Sci Rep. 2016;6.
   PubMed Web of Science ®Google Scholar
• Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. Targets Ther. 2017 Sep 29;10:403-412.doi.10.2147/DMSO.S141235.eCollection2017.
   PubMed Web of Science ®Google Scholar
• Haqq L, McFarlane J, Dieberg G, et al. Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis. Endocr Connect. 2014;3(1):1.
   PubMed Web of Science ®Google Scholar
• Lim SS, Hutchison SK, Van Ryswyk E, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;2019.
   Google Scholar
• Amanda NP, Km. The staggering true cost of diabetes [internet]. 2020. [cited 2021 Mar 21]. Available from: https://www.goodrx.com/blog/wp-content/uploads/2020/04/Diabetes-Cost-White-Paper.pdf
   Google Scholar
• Je D, Jp H, Tj R. Endothelial function and dysfunction. Circulation. 2007;115:10.
   Web of Science ®Google Scholar